Segment Information (Details) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2021 USD ($) segment	Sep. 30, 2020 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment							2
Segment Reporting Information [Line Items]
Total revenue	$ 121,340			$ 125,444			$ 358,597	$ 318,451
Total cost of revenue	74,101			71,379			216,794	190,011
Total gross profit	47,239			54,065			141,803	128,440
General and administrative	63,839			36,128			158,953	107,085
Research and development	7,409			1,964			13,360	6,129
Sales and marketing	15,704			11,304			46,677	34,757
Total operating expenses	86,952			49,396			218,990	147,971
Loss (income) from operations	(39,713)			4,669			(77,187)	(19,531)
Interest expense, net	1,296			2,458			3,375	4,825
Other income, net	(89)			(11)			(431)	(7,639)
Gain on investment in and loan receivable from non-consolidated affiliate, net	(17,750)			0			(109,260)	0
Loss on extinguishment of debt	0			0			0	1,400
Loss on termination of cash flow hedge	0			0			0	3,506
(Loss) income before taxes	(23,170)			2,222			29,129	(21,623)
Income tax benefit	(2,822)			(335)			(4,283)	(10,378)
Net (loss) income	(20,348)	$ 75,873	$ (22,114)	2,557	$ (6,824)	$ (6,978)	33,412	(11,245)
Clinical Services
Segment Reporting Information [Line Items]
Total revenue	102,227			108,733			300,119	275,599
Total cost of revenue	59,560			60,607			178,358	158,287
Total gross profit	42,667			48,126			121,761	117,312
Amortization of acquired intangible assets	4,300						5,000
Clinical Services | COVID-19 PCR Testing
Segment Reporting Information [Line Items]
Write off of COVID-19 PCR testing inventory							5,300
Pharma Services
Segment Reporting Information [Line Items]
Total revenue	19,113			16,711			58,478	42,852
Total cost of revenue	14,541			10,772			38,436	31,724
Total gross profit	4,572			$ 5,939			20,042	$ 11,128
Amortization of acquired intangible assets	$ 500						$ 500